1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
3
Active Trials
200 recruiting
3
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Juventas Cell Therapy Ltd. is a company with 1 orphan drug designation across 3 rare diseases. Active clinical trials in 3 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| adult acute lymphoblastic leukemia | Anti-CD19 Chimeric Antigen Receptor T-Cell Injection | Des.TrialAppr. |
| lupus erythematosus | - | Des.TrialAppr. |
| lymphoma | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
14
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
14
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio